Adding STRIDE and Lenvatinib to TACE Improved Disease Control in Liver Cancer

EMERALD-3: Disease Control Is Improving in Liver Cancer

Which patient group does this concern?

EMERALD-3 does not concern patients with early-stage hepatocellular carcinoma who are surgical candidates, but rather locoregional patients ineligible for curative treatment but eligible for embolization . In these patients, disease is confined to the liver, with no extrahepatic spread, and patients are eligible for intra-arterial local treatment such as TACE.

Participants were required to have Child-Pugh Aliver function and ECOG 0–1 performance status. Selection criteria also included no extrahepatic disease, significant portal vein thrombosis, or prior systemic therapy. Results must therefore be interpreted for patients with good liver reserve, suitable general condition, and eligibility for TACE.

Study design: a global, three-arm phase 3 trial

EMERALD-3 is a global, randomized, open-label, sponsor-blinded, multicenter phase 3 trial. A total of 760 patients, from 171 centers and 22 countries were enrolled. Patients were assigned to one of three treatment strategies.

Randomization initially followed a 1:1:1 ratio. Once each arm reached 175 patients, randomization continued between Arm A and Arm C at 1:1, strengthening the primary comparison of the four-component regimen with TACE alone.

The STRIDE regimen starts with a single initial dose of tremelimumab 300 mg and durvalumab 1500 mg , followed by durvalumab every 4 weeks . Through the HIMALAYA trial, this became an established immunotherapy backbone for advanced unresectable HCC.

Main result: four-component treatment raised PFS to 13 months

At the first data cutoff, on 2 September 2025 , PFS maturity was %63,8 . Arm A, namely TACE + STRIDE + lenvatinib, showed statistically significant superiority over TACE alone for the primary endpoint of PFS.

Median PFS in the four-component arm was 13,0 months, compared with 9,8 months in the TACE-alone arm . HR was 0,70, with p=0,0007 . This corresponds to approximately a 30% relative reduction in the risk of progression or death.

At month 12, PFS rates in the four-component arm were %56,2, versus %42,9 in the TACE-alone arm. At month 24, PFS rates were %30,4 and %19,3 . The difference is therefore maintained not only in median PFS but also at specific time points.

Overall survival: a favorable trend, but not yet established

After the PFS objective was met, overall survival between Arm A and Arm C was assessed at the second data cutoff, on 23 February 2026 . OS maturity in this analysis was %40,3 .

Median OS in the four-component arm was 39,5 months, compared with 34,7 months in the TACE-alone arm . HR was 0,84, with p=0,1814 . This is a numerically favorable trend, not a statistically established OS advantage.

The arm without lenvatinib: STRIDE + TACE is also noteworthy

An intriguing aspect of EMERALD-3 is the strong signal from Arm B without lenvatinib. However, this analysis has not yet been formally tested because of the hierarchical testing procedure; results must therefore be considered exploratory/descriptive.

In the STRIDE + TACE arm, median PFS was 12,9 months, compared with 8,1 months in the TACE-alone arm . HR was 0,71, with nominal p=0,0062 . PFS maturity was %75,1 .

Median OS was not reached in the STRIDE + TACE arm; in the TACE-alone arm, median OS was 32,9 months . HR was 0,70, with nominal p=0,0233 . OS maturity was %45,4 . This suggests a strong biological and clinical signal for STRIDE + TACE even without lenvatinib.

All main numerical results

Safety: benefit, but a greater side-effect burden

The safety profiles of the combinations in EMERALD-3 were reported as consistent with the known profiles of their component drugs. No new safety signal was highlighted. However, more serious side effects were more frequent with the combinations than with TACE alone.

According to MSK’s patient-information summary, more serious side effects were reported in STRIDE + lenvatinib + TACE at a rate of %63, compared with %19 for TACE alone. Common notable effects included expected toxicities such as hypertension, diarrhea, reduced appetite, and weight loss.

Historical context: is TACE still sufficient alone?

TACE has been a standard approach in embolization-eligible HCC for over twenty years. However, disease control lasts less than a year in most patients. The MSK summary also states that TACE controls cancer for less than a year in most patients, with median survival after treatment of approximately 2–2,5 years.

The key message of EMERALD-3 is therefore not replacement of TACE by systemic therapy, but transformation of TACE into a stronger strategy with systemic immunotherapy and targeted therapy. Killing tumor cells, TACE may release antigens; STRIDE may strengthen immune responses; lenvatinib may add pressure through angiogenesis and the tumor microenvironment.

Regulatory status: is this combination approved?

For patients, this distinction is crucial: EMERALD-3 provides strong phase 3 evidence, but does not mean immediate standard implementation in every country and center. Licensing, reimbursement, and guideline updates must be tracked separately.

Critical reading: how should these data be interpreted in balance?

Message for clinical practice

EMERALD-3 suggests that TACE’s future in embolization-eligible HCC may shift from a standalone local procedure to an integrated strategy with immunotherapy and targeted therapy. It must not, however, be regarded as a treatment automatically applied to every TACE candidate.

The most suitable patient has Child-Pugh A liver function, ECOG 0–1, no extrahepatic disease or main portal vein branch thrombosis, can tolerate TACE, and can be closely monitored for systemic treatment side effects.

Conclusion

EMERALD-3 showed that adding STRIDE and lenvatinib to TACE significantly improved progression-free survival in embolization-eligible hepatocellular carcinoma ineligible for curative treatment. Median PFS was 13,0 versus 9,8 months, HR 0,70, p=0,0007 .

OS analysis showed a numerical trend favoring four-component treatment, but median OS of 39,5 versus 34,7 months, with HR 0,84and p=0,1814 , has not yet reached statistical significance. Exploratory PFS and OS signals in the STRIDE + TACE arm suggest that simpler strategies without lenvatinib may also be considered in future discussions.

The study may reshape TACE’s future in HCC; actual implementation will be clarified through patient selection, liver reserve, toxicity management, regulation, and guideline updates.